| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | John Grimley Evans | |
| Jacqueline S Birks | |||
| P2860 | cites work | Donepezil for dementia due to Alzheimer's disease | Q24244938 |
| Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial | Q24555726 | ||
| “Mini-mental state” | Q25938989 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial | Q28343193 | ||
| Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review | Q30865349 | ||
| Rivastigmine for Alzheimer's disease. | Q33145821 | ||
| Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease | Q33821291 | ||
| Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology | Q34481807 | ||
| Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period | Q34559914 | ||
| Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease | Q34566087 | ||
| Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease | Q34571834 | ||
| IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease | Q34655376 | ||
| A review of rivastigmine: a reversible cholinesterase inhibitor | Q35177675 | ||
| A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease | Q35428213 | ||
| Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years | Q36107758 | ||
| Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. | Q36226630 | ||
| A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia | Q36998823 | ||
| Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. | Q37816073 | ||
| Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia | Q38225721 | ||
| What is the clinically relevant change on the ADAS-Cog? | Q38482318 | ||
| The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease | Q38801735 | ||
| The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
| Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis | Q39869678 | ||
| Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease | Q42642147 | ||
| Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. | Q42646907 | ||
| Determining the minimum clinically important differences for outcomes in the DOMINO trial. | Q42675662 | ||
| The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease | Q42912221 | ||
| Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression | Q43545903 | ||
| Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease | Q43609548 | ||
| Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease | Q43623541 | ||
| Rivastigmine in outpatient services: experience of 114 neurologists in Austria | Q43914842 | ||
| Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type | Q43944752 | ||
| A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances | Q43982779 | ||
| Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil | Q44048279 | ||
| Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial | Q44480551 | ||
| Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease | Q44542466 | ||
| Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial | Q44685512 | ||
| No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment | Q44700621 | ||
| Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease | Q44803116 | ||
| Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. | Q44828253 | ||
| Behavioral symptoms in mild cognitive impairment | Q44840318 | ||
| The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias | Q44975334 | ||
| A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease | Q45071385 | ||
| Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study | Q45088915 | ||
| Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. | Q45939476 | ||
| Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study | Q46193667 | ||
| Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease | Q46208023 | ||
| Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment | Q46892229 | ||
| Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease | Q48395487 | ||
| Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease | Q48439989 | ||
| Rivastigmine. A review of its use in Alzheimer's disease | Q48783638 | ||
| Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. | Q50780492 | ||
| Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis. | Q50860260 | ||
| The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. | Q51183354 | ||
| Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. | Q51910066 | ||
| Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents. | Q51965641 | ||
| Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. | Q51971493 | ||
| Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. | Q51977367 | ||
| Severe impairment battery. A neuropsychological test for severely demented patients. | Q52029498 | ||
| A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). | Q52033532 | ||
| Clock completion: an objective screening test for dementia. | Q52884214 | ||
| Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. | Q52915655 | ||
| Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. | Q53050714 | ||
| Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. | Q53285695 | ||
| Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. | Q53387830 | ||
| A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule | Q56637378 | ||
| Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease | Q56864656 | ||
| The Global Deterioration Scale for assessment of primary degenerative dementia | Q57279034 | ||
| An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors | Q58748656 | ||
| Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications | Q58748657 | ||
| Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease | Q59313801 | ||
| Validity of the Trail Making Test as an Indicator of Organic Brain Damage | Q64357777 | ||
| Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans | Q73247874 | ||
| Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks | Q73295785 | ||
| P921 | main subject | Alzheimer's disease | Q11081 |
| P577 | publication date | 2015-04-10 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Rivastigmine for Alzheimer's disease |
| Q37043396 | ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. |
| Q42370244 | Altering neuronal excitability to preserve network connectivity in a computational model of Alzheimer's disease |
| Q64081519 | Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease |
| Q58780915 | Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors |
| Q36054385 | Case Finding of Mild Cognitive Impairment and Dementia and Subsequent Care; Results of a Cluster RCT in Primary Care. |
| Q92771777 | Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry |
| Q97420209 | Discovery of a Selective 6-Hydroxy-1, 4-Diazepan-2-one Containing Butyrylcholinesterase Inhibitor by Virtual Screening and MM-GBSA Rescoring |
| Q92199453 | Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening |
| Q59135260 | Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials |
| Q90106489 | Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting |
| Q26744105 | Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease |
| Q26750581 | Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview |
| Q39370839 | Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants |
| Q88790824 | Oleanolic Acid Ameliorates Aβ25-35 Injection-induced Memory Deficit in Alzheimer's Disease Model Rats by Maintaining Synaptic Plasticity |
| Q91710367 | Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty |
| Q57178494 | Postmortem Brain, Cerebrospinal Fluid, and Blood Neurotrophic Factor Levels in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
| Q91762131 | Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer's disease |
| Q39580541 | Prevalence of Drug-Induced Xerostomia in Older Adults with Cognitive Impairment or Dementia: An Observational Study |
| Q36766861 | Real-world evaluation of compliance and preference in Alzheimer's disease treatment: an observational study in Taiwan. |
| Q89747430 | Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease |
| Q33596451 | Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia |
| Q57495012 | Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease |
| Q53398026 | Spore powder of Ganoderma lucidum for the treatment of Alzheimer disease: A pilot study. |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q60956699 | The Multidisciplinary Approach to Alzheimer's Disease and Dementia. A Narrative Review of Non-Pharmacological Treatment |
| Q36185198 | The Top 5 Neurotransmitters from a Clinical Neurologist's Perspective. |
| Q33165801 | The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease |
| Q92715035 | The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications |
Search more.